Incidence And Risk Of Pneumonitis Associated With Nivolumab And Pembrolizumab In Patients With Cancer: A Meta-Analysis Of Clinical Trials.

e21651Background: Anti PD-1 antibodies, nivolumab or pembrolizumab, have been approved for the treatment of a variety of malignant tumors including melanoma and non-small cell lung cancer (NSCLC). Pneumonitis has been described as a major adverse effect related with these agents, although the overall incidence and risk remain unclear. We performed a meta-analysis to characterize the overall incidence and risk of pneumonitis in cancer patients treated with these agents and to describe the relative risk compared with control. Methods: The electronic databases PubMed, Embase, Web of Science, Cochrane databases, and ASCO (American Society of Clinical Oncology) abstracts were searched for studies to include in the meta-analysis. Eligible studies were prospective phase II and III clinical trials of nivolumab or pembrolizumab with adequate safety data. Summary incidences, relative risk (RR), and 95% confidence intervals (CI) were calculated employing fixed or random effect models depending on the heterogeneity o...